Spruce Biosciences (SPRB) Change in Cash (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Change in Cash of $5.2 million for Q1 2026, up 139.38% year-over-year from $2.2 million in Q1 2025, and down 86.47% quarter-over-quarter from $38.2 million in Q4 2025.
Spruce Biosciences (SPRB) Change in Cash (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Change in Cash for 8 consecutive years, with $5.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 139.38% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $28.5 million (up 151.25% YoY), while the FY2025 annual figure was $10.2 million, up 117.63% from the prior year.
- Change in Cash declined to $5.2 million in Q1 2026 per SPRB's latest filing, from $38.2 million in the prior quarter.
- Across five years, Change in Cash topped out at $49.2 million in Q1 2023 and bottomed at -$25.6 million in Q3 2022.
- Historically, Change in Cash has averaged $656000.0 across 5 years, with a median of -$5.7 million in 2025.
- Annual changes were most pronounced in 2023 — Change in Cash jumped 353.66% — and 2024, when it sank 829.95%.
- Spruce Biosciences' Change in Cash stood at $2.9 million in 2022, then tumbled by 185.84% to -$2.5 million in 2023, then sank by 765.58% to -$21.3 million in 2024, then soared by 279.5% to $38.2 million in 2025, then slumped by 86.47% to $5.2 million in 2026.
- Business Quant data shows SPRB's Change in Cash at $5.2 million in Q1 2026, $38.2 million in Q4 2025, and -$5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | 42.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.22 Mn |
| Mar 31, 2026 | 5.17 Mn |
| Dec 31, 2025 | 38.24 Mn |
| Sep 30, 2025 | -5.72 Mn |
| Jun 30, 2025 | -9.23 Mn |
| Mar 31, 2025 | -13.14 Mn |
| Dec 31, 2024 | -21.30 Mn |
| Sep 30, 2024 | -9.63 Mn |
| Jun 30, 2024 | -11.47 Mn |
| Mar 31, 2024 | -15.19 Mn |
| Dec 31, 2023 | -2.46 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 23.56 Mn |
| Mar 31, 2023 | 49.22 Mn |
| Dec 31, 2022 | 2.87 Mn |
| Sep 30, 2022 | -25.56 Mn |
| Jun 30, 2022 | 23.87 Mn |
| Mar 31, 2022 | -19.41 Mn |
| Dec 31, 2021 | -15.62 Mn |
| Sep 30, 2021 | -19.92 Mn |